全部商品分类.jpg)
1/2
用小程序，查商品更便捷
产品介绍
产品介绍
产品信息
抗原名称
VEGFR2/Flk1
商品描述
Semaxanib (SU5416)是一种有效的，选择性的VEGFR(Flk-1/KDR)抑制剂，IC50为1.23 μM，作用于VEGFR比作用于PDGFRβ选择性高20倍，对EGFR， InsR和FGFR没有作用活性。
分子量
238.28
纯度
＞98%
可溶性
DMF : 50 mg/mL (209.84 mM; Need ultrasonic)
DMSO : 20 mg/mL (83.93 mM; Need ultrasonic)
DMSO : 20 mg/mL (83.93 mM; Need ultrasonic)
外观
yellow to yellow orange solid
In vitro(体外研究)
Semaxanib inhibits VEGF-dependent phosphorylation of the Flk-1 receptor in Flk-1-overexpressing NIH 3T3 cells with IC50 of 1.04 μM. Semaxanib inhibits PDGF-dependent autophosphorylation in NIH 3T3 cells with IC50 of 20.3 μM. Semaxanib inhibits VEGF- and FGF-driven mitogenesis in a dose-dependent manner with IC50 of 0.04 and 50 μM, respectively. Semaxanib treatment has no effect on the in vitro growth of C6 glioma, Calu 6 lung carcinoma, A375 melanoma, A431 epidermoid carcinoma, and SF767T glioma cells (all IC50s > 20 μM).
In vivo(体内研究)
Semaxanib dose-related inhibits growth of A375 tumor in vivo. A >85% inhibition of subcutaneous tumor growth is observed with daily i.p. administration of SU5416 in DMSO at Semaxanib, without measurable toxicity. Semaxanib shows broad spectrum antitumor activity. SU5416 significantly inhibits the subcutaneous growth of 8 of 10 tumor lines tested (A431, Calu-6, C6, LNCAP, EPH4-VEGF, 3T3HER2, 488G2M2 and SF763T cells) with an average mortality rate of 2.5%. Semaxanib (25 mg/kg/day) displays potent antiangiogenic activity, resulting in a significant reduction of both the total and functional vascular density of the tumor microvasculature.
背景
别名
司马沙尼；SU5416
分子式
C15H14N2O
CAS号
204005-46-9
制备和贮存
保存方式
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
参考图片
声明 ：本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。